Literature DB >> 18221909

CD4+ T helper responses in squamous cell carcinoma of the head and neck.

Kazuaki Chikamatsu1, Koichi Sakakura, Takanori Yamamoto, Nobuhiko Furuya, Theresa L Whiteside, Keisuke Masuyama.   

Abstract

Anti-tumor immunity plays an important role in the development of and protection from malignancy. However, there is a lack of information regarding induction of CD4+ T helper responses in patients with squamous cell carcinoma (SCCHN). To explore anti-tumor immune responses against SCCHN, a permanent cell line, Gun-1 was established from a squamous cell carcinoma of the hypopharynx. In addition to its characterization, we performed mixed lymphocyte-tumor cell cultures (MLTC) using peripheral blood lymphocytes and autologous tumor cells. Furthermore, T cell responses to wild type (wt) p53-derived peptides were assessed. Gun-1 cells overexpressed p53 and were negative for HLA-A2 expression. No tumor-specific or wt p53-specific CD8+ CTL lines could be established from peripheral blood mononuclear cells (PBMCs) of this patient. Autologous tumor-specific HLA-DR-restricted CD4+ T helper clone was obtained by limiting dilutions using bulk populations from MLTC. This clone produced IFN-gamma but not IL-5 in response to autologous tumor cells. In addition, CD4+ T cells were generated from the patient's PBMCs which responded to two HLA-DP5-restricted wt p53-derived peptides. Our results suggest that the immune cells specific for autologous tumor as well as wt p53-derived epitopes are present in the peripheral circulation of this cancer patient. However, helper-type CD4+ T lymphocytes represent the predominant anti-tumor response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18221909      PMCID: PMC3721335          DOI: 10.1016/j.oraloncology.2007.11.001

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  30 in total

1.  Alterations in the T-cell receptor variable beta gene-restricted profile of CD8+ T lymphocytes in the peripheral circulation of patients with squamous cell carcinoma of the head and neck.

Authors:  Andreas E Albers; Carmen Visus; Takashi Tsukishiro; Robert L Ferris; William Gooding; Theresa L Whiteside; Albert B De Leo
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck.

Authors:  Koichi Sakakura; Kazuaki Chikamatsu; Katsumasa Takahashi; Theresa L Whiteside; Nobuhiko Furuya
Journal:  Cancer Immunol Immunother       Date:  2005-05-12       Impact factor: 6.968

3.  Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome.

Authors:  Markus Meissner; Torsten E Reichert; Martin Kunkel; William Gooding; Theresa L Whiteside; Soldano Ferrone; Barbara Seliger
Journal:  Clin Cancer Res       Date:  2005-04-01       Impact factor: 12.531

4.  A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.

Authors:  M Eura; K Chikamatsu; F Katsura; A Obata; Y Sobao; M Takiguchi; Y Song; E Appella; T L Whiteside; A B DeLeo
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

Review 5.  Immunobiology of head and neck cancer.

Authors:  Theresa L Whiteside
Journal:  Cancer Metastasis Rev       Date:  2005-01       Impact factor: 9.264

6.  Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.

Authors:  C N Baxevanis; I F Voutsas; O E Tsitsilonis; A D Gritzapis; R Sotiriadou; M Papamichail
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

7.  Induction and large-scale expansion of CD8+ tumor specific cytotoxic T lymphocytes from peripheral blood lymphocytes by in vitro stimulation with CD80-transfected autologous melanoma cells.

Authors:  A Mackensen; S Wittnebel; H Veelken; C Noppen; G C Spagnoli; A Lindermann
Journal:  Eur Cytokine Netw       Date:  1999-09       Impact factor: 2.737

8.  Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens.

Authors:  Josef Mautner; Elizabeth M Jaffee; Drew M Pardoll
Journal:  Int J Cancer       Date:  2005-07-10       Impact factor: 7.396

9.  Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.

Authors:  Koichi Sakakura; Kazuaki Chikamatsu; Nobuhiko Furuya; Ettore Appella; Theresa L Whiteside; Albert B Deleo
Journal:  Clin Immunol       Date:  2007-07-12       Impact factor: 3.969

10.  CD4 T cells and their role in antitumor immune responses.

Authors:  R E Toes; F Ossendorp; R Offringa; C J Melief
Journal:  J Exp Med       Date:  1999-03-01       Impact factor: 14.307

View more
  4 in total

1.  Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms.

Authors:  Hiroki Ishii; Masao Saitoh; Kei Sakamoto; Tetsuo Kondo; Ryohei Katoh; Shota Tanaka; Mitsuyoshi Motizuki; Keisuke Masuyama; Keiji Miyazawa
Journal:  J Biol Chem       Date:  2014-08-20       Impact factor: 5.157

2.  Relationship between tumor-associated macrophage subsets and CD47 expression in squamous cell carcinoma of the head and neck in the tumor microenvironment.

Authors:  Koichi Sakakura; Hideyuki Takahashi; Kyoichi Kaira; Minoru Toyoda; Takaaki Murata; Hiroshi Ohnishi; Tetsunari Oyama; Kazuaki Chikamatsu
Journal:  Lab Invest       Date:  2016-06-20       Impact factor: 5.662

3.  Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck.

Authors:  Kazuaki Chikamatsu; Goro Takahashi; Koichi Sakakura; Soldano Ferrone; Keisuke Masuyama
Journal:  Head Neck       Date:  2011-02       Impact factor: 3.147

4.  Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases.

Authors:  S H Kim; F Castro; D Gonzalez; P C Maciag; Y Paterson; C Gravekamp
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.